Literature DB >> 34269934

Is salvage surgery for large vestibular schwannomas after failed gamma knife radiosurgery more challenging?

Lucas Troude1, Mohamed Boucekine2, Anne Balossier3, Guillaume Baucher4, Jean-Pierre Lavieille4, Jean Régis3, Pierre-Hugues Roche4.   

Abstract

In order to verify whether a previous gamma knife surgery (GKS) treatment could influence the oncological and functional outcome in large vestibular schwannoma (VS) surgery, we have compared group of patients operated on for large VS after failed GKS to a group of genuine VS that underwent the same functional nerve-sparing resection technique regimen in the same period. Single center retrospective cohort study of 23 consecutive GKS failure and 170 genuine VS patients operated on between April 2003 and March 2019. After resection, patients were allocated to a Wait-&-rescan or an upfront GKS policy. At last follow-up examination, the facial nerve function was good (House-Brackmann grades I or II) in 95% of the GKS failure and 84% of the genuine VS patients (p = .25). The median volume of tumor residue was .56 cc in the GKS failure group and .62 cc in the genuine VS group (p = .70). Tumor control was achieved in 91% and 83% of cases with a mean follow-up of 74 and 63 months in the GKS failure and the genuine VS populations, respectively. The 1-, 5-, and 7-year progression-free survival were 100%, 95%, and 85% respectively in the GKS failure group and 97%, 80%, and 81% in the genuine VS group (p = .27). Despite significant modifications of the microsurgical environment associated to salvage surgery after GKS failure, a functional nerve-sparing resection is an effective strategy to optimize the results on facial nerve function, with similar long-term tumor control to those observed in the genuine VS population.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Facial nerve; Failed radiosurgery; Gamma knife Surgery; Salvage surgery; Subtotal resection; Tumor control; Vestibular schwannoma

Mesh:

Year:  2021        PMID: 34269934     DOI: 10.1007/s10143-021-01604-3

Source DB:  PubMed          Journal:  Neurosurg Rev        ISSN: 0344-5607            Impact factor:   3.042


  5 in total

1.  Predictive Factors of Early Postoperative and Long-Term Facial Nerve Function After Large Vestibular Schwannoma Surgery.

Authors:  Lucas Troude; Mohamed Boucekine; Marion Montava; Jean-Pierre Lavieille; Jean-Marie Régis; Pierre-Hugues Roche
Journal:  World Neurosurg       Date:  2019-03-28       Impact factor: 2.104

Review 2.  The Surgeon in Action: Representations of Neurosurgery in Movies from the Frères Lumière to Today.

Authors:  Florian Bernard; Guillaume Baucher; Lucas Troude; Henri-Dominique Fournier
Journal:  World Neurosurg       Date:  2018-07-30       Impact factor: 2.104

3.  Treatment Results of Gamma Knife Radiosurgery for Central Neurocytoma: Report of a Japanese Multi-Institutional Cooperative Study.

Authors:  Kazuhiro Yamanaka; Yoshiyasu Iwai; Takashi Shuto; Yoshihisa Kida; Mitsuya Sato; Motohiro Hayashi; Takeshi Kondo; Hisao Hirai; Rentaro Hori; Kenji Kubo; Hisae Mori; Osamu Nagano; Toru Serizawa
Journal:  World Neurosurg       Date:  2016-03-14       Impact factor: 2.104

4.  Microsurgical removal of a vestibular schwannoma after stereotactic radiosurgery: surgical and pathologic findings.

Authors:  M Schulder; G S Sreepada; J A Kwartler; E S Cho
Journal:  Am J Otol       Date:  1999-05

Review 5.  Hearing preservation in unilateral acoustic neuroma surgery.

Authors:  G Gardner; J H Robertson
Journal:  Ann Otol Rhinol Laryngol       Date:  1988 Jan-Feb       Impact factor: 1.547

  5 in total
  1 in total

1.  Stereotactic radiosurgery for Koos grade IV vestibular schwannoma in young patients: a multi-institutional study.

Authors:  Chloe Dumot; Stylianos Pikis; Georgios Mantziaris; Zhiyuan Xu; Rithika Kormath Anand; Ahmed M Nabeel; Darrah Sheehan; Kimball Sheehan; Wael A Reda; Sameh R Tawadros; Khaled Abdel Karim; Amr M N El-Shehaby; Reem M Emad Eldin; Selcuk Peker; Yavuz Samanci; Tehila Kaisman-Elbaz; Herwin Speckter; Wenceslao Hernández; Julio Isidor; Manjul Tripathi; Renu Madan; Brad E Zacharia; Lekhaj C Daggubati; Nuria Martínez Moreno; Roberto Martínez Álvarez; Anne-Marie Langlois; David Mathieu; Christopher P Deibert; Vivek R Sudhakar; Christopher P Cifarelli; Denisse Arteaga Icaza; Daniel T Cifarelli; Zhishuo Wei; Ajay Niranjan; Gene H Barnett; L Dade Lunsford; Greg N Bowden; Jason P Sheehan
Journal:  J Neurooncol       Date:  2022-09-27       Impact factor: 4.506

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.